IN BRIEF: GSK completes acquisition of Sierra Oncology
1st Jul 2022 15:37
GSK PLC - London-based pharmaceutical company - Completes acquisition of Sierra Oncology Inc, for USD55 per share in cash, representing a total value of USD1.9 billion. Notes acquisition includes momelotinib, a late-stage potential treatment for myelofibrosis patients with anaemia. Last month, Sierra presented data for the treatment from phase III Momentum trial, which met all its key primary and secondary endpoints. The drug showed a statistically meaningful benefit on symptoms, splenic response, and anaemia. Read More